Skip to main content
. 2019 Jul 22;11(7):1028. doi: 10.3390/cancers11071028

Table 2.

Strategy of targeting BCSCs associated with endocrine therapy resistance.

Method BCSC Model Action Ref.
TRAIL Tamoxifen 1 Xenograft and PDX Death receptor [232]
Pyrvinium pamoate CD44+CD24−/low
ALDH+ 		Xenograft Wnt inhibitor [233]
Reparixin ALDH+ Xenograft Agonist of CXCR1/2 [205]
Dasatinib + venetoclaz BCSCs In vitro Src inhibitor
BCL2 inhibitor		 [235]

1 BCSCs were derived from tamoxifen resistant tumors.